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Abstract
Background: It is known that all tumors studied in sufficient number to draw conclusions show characteristic/
specific chromosomal rearrangements, and the identification of these chromosomes and the genes rearranged
behind the aberrations may ultimately lead to a tailor-made therapy for each cancer patient. Knowledge about the
acquired genomic aberrations of ovarian carcinomas is still unsatisfactory.
Methods: We cytogenetically analyzed 110 new cases of ovarian carcinoma of different histological subtypes using
karyotyping of G-banded chromosomes and high-resolution comparative genomic hybridization. We first compared
the aberration patterns identified by the two genomic screening techniques using the so-called “classical” pathological
classification in which the carcinomas are grouped as tumors of types I and II. We also broke down our findings
according to the more “modern” classification which groups the carcinomas in five different categories.
Results: The chromosomal breakpoints identified by karyotyping tended to cluster to 19p/q and to 11q, but no
unquestionably recurrent rearrangement could be seen. Common imbalances were scored as gains from 1q, 3q,
7q, and 8q and losses from 17p, 19q, and 22q. Gain of material from 8q23 and losses from 19q and 22q have
previously been described at high frequencies in bilateral and borderline ovarian carcinomas. The fact that they
were present both in “precursor” lesions, i.e., borderline tumors, as well as in tumors of more advanced stages, i.e.,
carcinomas, highlights the possibility of an adenoma-carcinoma sequence in ovarian carcinogenesis.
Conclusion: Based on the relatively simple genomic changes we identified in the low-grade serous carcinomas
examined (n = 7) and which largely corresponded to the aberration pattern formerly identified in borderline
tumors, one can interpret the cytogenetic data as supporting the view that the low-grade carcinomas represent a
phenotypically more advanced stage of borderline tumors. Whether transition from low-grade to high-grade
carcinoma also occurs, is a question about which the genomic data is still inconclusive.
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Background
Cancer of the ovary represents 30% of all cancer of the
female genital organs [1]. Adenocarcinomas make up
75% of all ovarian tumors and 95% of ovarian malignan-
cies [1]. At the same time, surface epithelial tumors of
the ovary display a wide variety of histologic types which
may reflect pathogenetic variability and/or differences
among the cell(s) of origin. One potentially useful way of
classifying these neoplasms is to divide them into those
that appear to develop from benign and/or atypical
proliferative precursor lesions (mucinous, endometrioid,
clear cell, and low-grade serous carcinomas, also referred
to as type I tumors) and those that appear to develop de
novo (high-grade serous carcinomas or type II tumors)
[2,3]. However, the apparent difference between serous
and nonserous tumors in this regard may reflect the rapid-
ity of the adenoma-carcinoma transition rather than any
qualitative pathogenetic difference. Specifically, it can be
argued that the adenoma-carcinoma sequence for serous
tumors is variable but, on average, shorter than that for
mucinous, endometrioid, and clear-cell tumors; this would
explain the relative uniformity of serous carcinomas and
the infrequent presence in them of neoplastic precursor
lesions [2]. It is obvious that use of the term “de novo” in
this context reflects our ignorance about the early events
of ovarian carcinogenesis rather than real insight into the
tumor origin.
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At the same time, pathologists also classify ovarian
carcinomas into five main types based on histopatho-
logical, immunohistochemical, and molecular genetic
findings: high-grade serous carcinomas, endometrioid
carcinomas, clear-cell carcinomas, mucinous carcinomas,
and low-grade serous carcinomas [4]. The tumors be-
longing to these categories account for 98% of ovarian
carcinomas. They differ group-wise from one another
also with regard to epidemiological and genetic risk fac-
tors, precursor lesions, patterns of spreading, molecular
events during oncogenesis, response to chemotherapy,
and prognosis [4].
Many of the more than 400 (at the moment 438) sci-
entifically reported ovarian carcinomas with karyotypi-
cally characterized chromosomal aberrations [5] were
examined as abdominal effusions, that is at a very late
stage in tumor progression, and many were incom-
pletely karyotyped. Knowledge about the chromosomal
characteristics of this type of cancer is therefore far
from complete.
We here present 110 new cases of ovarian carcinoma
of different histologic subtypes (73 high-grade serous
carcinomas, seven low-grade serous, 15 endometrioid,
eight clear-cell, three mucinous, three mixed endome-
trioid and mucinous, and one undifferentiated carcinoma)
whose genome was characterized by G-banding followed
by karyotyping and high-resolution comparative genomic
hybridization (HR-CGH). We specifically compared the
acquired genomic aberration pattern of the high-grade
serous carcinomas with that of the other types in order to
address the question if they share common genomic ab-
normalities and therefore have a common/similar patho-
genesis or, alternatively, if the high-grade serous tumors
warrant being considered as a wholly distinct entity. We
also scrutinized the aberration patterns of the five different
subgroups to identify whatever genomic aberrations might
distinguish each group or if any are common to two or
more ovarian carcinoma types.
Methods
Tumors
The material consisted of fresh samples from 110 primary
ovarian carcinomas surgically removed at The Norwegian
Radium Hospital from 1999 to 2004 (Additional file 1:
Table S1). Neoadjuvant therapy had been given in 25 of
the cases before surgery (Additional file 1: Table S1).
The tumors were classified as high-grade serous adenocar-
cinoma (73 samples), low-grade serous adenocarcinoma
(seven samples), endometrioid carcinoma (15 samples),
clear-cell carcinoma (eight samples), mucinous carcinoma
(three samples), undifferentiated carcinoma (one sample),
and mixed histology between endometroid and mucinous
carcinoma (three samples and cases).
The project has been approved by the Regional Ethics
Committee for Medical and Health Research Ethics South-
East in the year 2007 (project number 2.2007.425). Written
informed consent was obtained from the patients. Frozen
tissue was retrieved from The Radium Hospital biobank
(nr 1971, S-07194a approved by the Regional Ethics Com-
mittee and The Directory of Health (Helsedirektorat) in
2007). The entire study was also approved by the institu-
tional review board at the Norwegian Radium Hospital.
Cell culturing and karyotyping
The tumor samples were manually minced and disaggre-
gated with Collagenase II (Worthington, Freehold, NJ,
USA) until a suitable suspension of cells and cell clumps
was obtained. After 6-7 days of culturing in a selective
medium [6], colchicine was added and the cultures har-
vested according to Mandahl [7]. The chromosomes of
the dividing cells were then G-banded and a karyotype
established according to the recommendations of the
ISCN [8].
High-resolution comparative genomic hybridization
(HR-CGH)
DNA was isolated by the phenol-chloroform method as
previously described [9]. CGH was performed according
to our modifications of standard procedures [10,11].
Chromosomes were karyotyped based on their inverted
DAPI appearance and the relative hybridization signal
intensity was determined along each chromosome. On
average, 10-15 metaphases were analyzed. The HR-CGH
analysis was performed as previously described [12]. The
description of the CGH copy number changes was based
on the recommendation of the ISCN [8].
Results
Karyotypic information was obtained on 86 of the original
110 samples (Additional file 1: Table S1). The 24 cultures
that failed showed either no cell attachment after several
days in vitro or no metaphases. A normal karyotype was
found in 22 tumors. The remaining 64 tumors (Additional
file 1: Table S1) mostly showed complex karyotypes with
several structural and numerical aberrations. Simple
karyotypes, by which we mean karyotypes showing less
than four aberrations, were seen only in one high-grade
serous carcinoma (case 35), two low-grade serous car-
cinomas (cases 77 and 78), one clear-cell carcinoma
(case 102), and one mixed endometrioid and mucinous
carcinoma (case 107). Case 35 (a high-grade serous
tumor) showed monosomies of chromosomes X, 4, and
10. Case 77 (a low-grade serous tumor) showed two
unrelated clones with monosomy 11 and monosomy of
the X chromosome, respectively. Case 78 (a low-grade
serous tumor) showed trisomy 7 as the sole abnormality
in all cells analyzed. Case 102 (a clear-cell tumor) had
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two supernumerary markers of unknown origin in three
metaphases of the 45 cells analyzed. Case 107 (also a
mixed endometrioid and mucinous carcinoma) showed
additional material of unknown origin on 8q24 as the sole
chromosomal abnormality. The only tumor showing obvi-
ous clonal evolution (i.e., beyond having several aberra-
tions) was case 38 (a high-grade serous carcinoma) which
had three related clones with only numerical aberrations
corresponding to the karyotype 47 ~ 49,XX,+8,+9[2]/49,
idem,+5,-6,+7[4]/54,idem,+3,+5,+6,+7,+14,+17,+19[5].
Breakpoint clusters were seen at chromosome arms 11q
(33 out of altogether 431 breaks, 7.65%), 19p (27 breaks;
6.26%), and 19q (22 breaks; 5.1%). The aberrations in-
volving these chromosomes were of different types, e.g.,
deletions, translocations, and additions of unknown ma-
terial. Although simple rearrangements between two
chromosomes could be described in some tumors, in
the majority of cases it was not possible to identify the
partner chromosome in the rearrangement which led us
to resort to descriptions such as add(11)(p/q) and/or
add(19)(p/q).
The HR-CGH analysis of genomic imbalances showed
gains and/or losses in 81 tumors (Additional file 1:
Table S1), whereas no imbalances were scored in seven
samples. No informative results were obtained in another
seven tumors due to poor quality of hybridization signals.
In the remaining 15 cases, no DNA was available to per-
form the analysis. Gains were more frequent than losses
and amplifications, i.e., more than four-fold gains, were
scored in 30 tumors (21 high-grade serous carcinomas,
four endometrioid, two clear-cell, one low-grade serous,
one mucinous, and one undifferentiated carcinoma). The
high-grade serous carcinomas (n = 56 with imbalances)
mostly showed gains of 3q26-27 (detected in 25% of the
tumors with imbalances), followed by gains of 3q24-25
and 8q23 (in 23%), and 1q31-32, 3q23, 3q28, 7q31-32,
8q24, and 12p12 (all detected in 21% of the tumors;
Figure 1). The most frequent losses were scored at 17p12
(21%), 17p11, 17p13, and 22q12-13 (20%), and 5q14, 6q24,
and 16q22 (18%). The endometrioid carcinomas (n = 12
with imbalances) showed gains of 1q23 (83% of the endo-
metrioid tumors with imbalances), followed by 1q24 and
8q22 (75%), 1q32 (67%), 1q21-22, 1q25-31, 1q41-42,
8q13-21, and 8q23q24 (58%), and 2q23-24, 3q13, 3q25-26,
6p12, 8q12, and 20p11 (50%; Figure 1). Losses were scored
at 1p36 (75%) followed by 19p13 and 22q (67%), and 9q22,
9q34, 12q23-24, 17p12-13, 17q21, 19q13, and 21q22
Figure 1 Profiles of the imbalances detected by HR-CGH in the
different subtypes of ovarian carcinomas. The green color
highlights gains, while the red color indicates losses. A) high-grade
serous carcinomas; B) low-grade serous carcinomas; C) endometrioid
carcinomas; D) clear-cell carcinomas; and E) mucinous carcinomas.
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(58%). The clear-cell carcinomas (n = 5 tumors with im-
balances) showed frequent gains from 1q23-32, 2p24,
2p21, 2q14-22, 5p13-15, 7p14-21, 8q12-24, and 10q21-22
(80%) followed by 1q41-44, 2p22-23, 2p13, 2q12-13, 2q23-
32, 3q13-24, 5q12-23, 5q32-34, 7p13, 7q21-34, 8q11,
10q11, 10q23-25, 12p11-13, 17q22-23, 19q13, 20q, and
22q11-12 (60%). Losses were most often scored at 4q21,
6p21, and 13q21 (80%) followed by 4q22-31, 6p22, 6q25-
26, 13q12-14, 13q22-32, and 16p13 (60%; Figure 1). The
mucinous carcinomas (n = 3 with imbalances) showed fre-
quent gains of 7q22-31, 7q34, and 8q23 (67%). Losses
were scored at 19p13, 19q13, and 22q11-12 in all
three tumors with imbalances (100%) followed by
losses of 7q11, 11q13, 12q24, 17p12-13, and 22q13
(67%; Figure 1). The low-grade serous carcinomas (n = 3
with imbalances) had gains mostly of 1q24, 7p13-21,
and 7q21-35 (67%), while losses were commonly de-
tected at 11q13, 17p12-13, 17q12-21, 22q12-13, and
Xq12-13 (67%; Figure 1). Amplifications most fre-
quently involved chromosomal bands 3q26 (12 tumors)
followed by 8q23 (11 tumors), 8q22 (ten tumors), 8q24
(eight tumors), and 3q25 and 8q21 (seven tumors). The
high-grade serous carcinomas showed amplifications
in 3q26 in ten samples followed by 8q23 (n = 9), 8q22
(n = 8), 8q24 (n = 7), and 3q25 and 8q21 in six samples
each. Four endometrioid carcinomas showed amplifi-
cation, case 84 (Additional file 1: Table S1) in 3q26 and
12p, case 85 in 1q42-44, case 90 in 5p14, and case 93 in
3q25-29 and 6p21-22. Two clear-cell carcinomas
showed amplifications: case 97 in 8q and case 100 in
8q13-21 and 8q22-23. The only low-grade serous car-
cinoma showing amplification (case 75) had it in 1q31,
the undifferentiated carcinoma (case 110) showed amp-
lification in 12q13, and a mucinous carcinoma (case
104) had 7q31 amplified.
Both tumors that had received (n = 15) and those that
had not received (n = 41) neo-adjuvant therapy prior to
the operation showed frequent gains from 3q and 7q;
however, the neo-adjuvant group also showed gain of
11q14-22 in 27% of the abnormal cases, whereas the
group that did not receive such treatment showed com-
mon additional gains from 1q, 2q, 8q, and 12p. Losses
were often seen at 8p, 9q, and 10q in the neo-adjuvant
subgroup but more commonly at 3p, 5q, 6q, 17p, 17q,
and 22q in the normal group.
The average number of copy aberrations (ANCA) index
was 39.7 for the high-grade serous carcinomas, 14.7 for
the low-grade serous carcinomas, 33.7 for the endome-
trioid carcinomas, 35.2 for the clear-cell carcinomas, and
20.3 for the mucinous carcinomas. The ANCA index for
the tumors (all subtypes taken together) that had received
neoadjuvant treatment was 30.85 whereas the value for
the group of tumors without neoadjuvant treatment
was 39.01.
Discussion
We report the analysis of 110 ovarian carcinomas of differ-
ent histological types using G-banding and HR-CGH. We
first compared the aberration patterns identified by the
two genomic screening techniques using the so-called
“classical” pathological classification of ovarian carcinomas
advocated by Blaustein [2] where the carcinomas are di-
vided into tumors of types I and II. We also broke down
our findings according to the more “modern” classification
proposed by Prat [4], which classifies the carcinomas into
five different categories.
The overall genomic complexity of the tumors could
be assessed both by karyotyping and CGH. The acquired
aberrations detected by G-banding resulted in complex
karyotypes in the great majority of both type I and type
II ovarian carcinomas. Breakpoint clusters were seen
first and foremost at 11q, 19p, and 19q. A total of five
rearrangements between chromosomes 11 and 19 (in
altogether three tumors) were detected in this series;
these have been examined in detail previously and re-
ported by us [6]. In our experience with ovarian cancer
karyotyping, this is the most common exchange of ma-
terial between two chromosomes detectable with this
technique. Lately, Onkes et al. [13] described a fusion
gene corresponding to a der(19)t(11;19)(q13.2;p13.2) in
the ovarian cell line SKOV3. The translocation led to a
fusion between the Homo sapiens hook homolog 2
(HOOK2), mapping on 19p, and the actinin alpha 3
(ACTN3), mapping on 11q. We have tested, using PCR-
based methods, all 110 samples of the present series for
this fusion whose chromosome-level rearrangement
could possibly be hidden in the complex and only par-
tially described karyotypes. However, we found no ex-
pression of this fusion gene in any of the tumors (data
not shown). Possibly other genes mapping to 11q and
19p are involved in fusions; this needs to be further
investigated.
With or without recombination with 11q, alterations
of chromosome bands 19p13 and 19q13 are among the
most frequent cytogenetic changes observed in ovarian
carcinomas as first pointed out by Pejovic et al. [14],
Jenkins et al. [15], and Thompson et al. [16]. Much later,
we subjected a group of ovarian carcinomas showing
additional material of unknown origin sitting on 19p/q
to examination by microdissection followed by reverse
in situ hybridization and were able to identify the nature
of the rearrangements in more detail [6]. We also per-
formed arrayCGH to identify the genomic regions that
were gained or amplified on the structurally rearranged
19p/19q [17]. However, much more remains to be done
to understand how the nonrandom 19p/q-changes con-
tribute to ovarian carcinogenesis.
There was no difference in breakpoint clusters among
the various histologic subtypes, i.e., they all had tumors
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with breakpoints clustering to 11q, 19p, and 19q. One
should be cognizant of the caveat, however, that the
great complexity of the rearrangements, as illustrated
by the presence of many markers in most karyotypes,
may have hidden rearrangements that could possibly
distinguish between the different tumor subtypes. When
we looked specifically at the serous subtype, we saw that
the low-grade tumors (n = 7) with informative karyo-
types (n = 5) were either cytogenetically normal (cases
79 and 80) or had only simple karyotypic aberrations
(less than four per karyotype in cases 76, 77, and 78).
On the other hand, the high-grade serous carcinomas
(n = 73) showed mostly complex and/or incomplete kar-
yotypes if they were not cytogenetically normal, the only
exception being case 35 which showed monosomies for
chromosomes X, 4, and 10 in three cells. These results
are in accordance with the findings in a previous study
of ours [12] in which we analyzed borderline ovarian
carcinomas of the serous and mucinous subtypes and
found only simple karyotypic changes. Furthermore, the
results support the suggestion of Prat [4] that low-grade
serous carcinomas can be defined as uncommon ovarian
carcinomas that show a noninvasive serous borderline
component, and that they most likely reflect progression
of serous borderline tumors beyond microinvasion.
The most reliable assessment of genomic complexity
in terms of gains/losses of chromosomal material was
obtained by HR-CGH. We compared tumor subsets
according to their ANCA index which was 29.8 for type
I and 39.7 for type II carcinomas. The Mann-Whitney
U-test showed a significant difference between the two
groups (p < 0.05; Table 1). The same test was also per-
formed to see if there were significant differences in
genomic complexity among the histologic subtypes
(Table 1). The only significant difference was found
between high- and low-grade serous carcinomas, with
the latter tumors on average showing fewer genomic
imbalances (ANCA index 39.7 vs 14.7). Obviously,
larger sets of samples for each specific subtype should
be tested to confirm or refute this conclusion. The same
non-parametric test was also performed to see if there
was a difference in the number of acquired chromosomal
aberrations between tumors that had received (n = 15) or
had not received (n = 41) neo-adjuvant therapy prior to
the operation. There was no statistical significance
(p = 0.29). However, the Mann-Witney U-test did show a
significant difference (p = 0.04) between the number of
copy number changes, i.e., the ANCA index, in the two
groups.
The imbalance patterns detected by HR-CGH were
also assessed group-wise with comparisons between type
I and type II tumors as well as among all five histologic
carcinoma subtypes. The high-grade serous carcinomas
(type II) mostly showed gains from 1q, 3q, 7q, 8q, and
12p but losses from 3p, 5q, 6q, 16q, 17p, 18q, 19q, and
22q, whereas the low-grade tumors (i.e., the remainder)
showed gains from 1q, 2q, 5q, and 8q whereas losses
were seen primarily from 1p, 9q, 11q, 12q, 16p, 17p,
19p, 19q, and 22q. Common imbalances to both type I
and type II were gains from 1q, 3q, 7q and 8q and losses
from 17p, 19q, and 22q. These results are in agreement
with the result of previous imbalance studies of ovarian
carcinomas [18-24] as well as with the latest research
work performed by the Cancer Genome Atlas Research
Network [25] on more than 400 ovarian carcinomas.
Furthermore, gain of material from 8q23 and losses from
19q and 22q have been found at high frequencies in bi-
lateral ovarian carcinomas where it was suggested that
they probably represent early genomic changes because
they were present in tumors of both sides [18]. The very
same imbalances were also identified in borderline ovarian
carcinomas [12]. The fact that they were present both in
“precursor” lesions, i.e., borderline tumors, as well as more
advanced stages, i.e., carcinomas, highlights the possibility
of an adenoma-carcinoma sequence in ovarian carcino-
genesis. The relationship between borderline ovarian tu-
mors and low-grade carcinomas has been investigated
at the gene level by many groups [26-28] focusing on
the mutually exclusive mutations detected in either the
BRAF or KRAS gene, and a relationship was found be-
tween the two groups of tumors. We did not perform any
molecular study on our cases; however, our chromosomal
results fit the interpretation that a common relationship
may exist between the two groups of tumors at the level of
both genes and chromosomes.
When looking separately at the imbalance patterns of
different subtypes of low-grade tumors, we saw examples
of gains and/or losses shared by two or more subtypes
Table 1 Overview of the p values obteined by comparing the ANCA index of the different histological subtypes of
ovarian carcinomas, using the Mann-Whitney U-test
High-grade serous Low-grade serous Endometrioid Clear cell Mucinous
High-grade serous – p = 0.03372 p = 0.2772 p = 0.624 p = 0.0874
Low-grade serous p = 0.03372 – p = 0.1486 p = 0.1771 p = 0.5066
Endometrioid p = 0.2772 p = 0.1486 – p = 0.8329 p = 0.3648
Clear cell p = 0.624 p = 0.1771 p = 0.8329 – p = 0.2938
Mucinous p = 0.0874 p = 0.5066 p = 0.3648 p = 0.2938 –
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but also copy number changes that were only or predom-
inantly present in one subgroup, namely -Xq mostly in
low-grade serous carcinomas, +6p, +20p, and -21q mostly
in endometrioid carcinomas, and +2p, +5p, +5q, +10q,
+12p, +17q, +19q, +20q, -4q, -6p, and -13q mostly in
clear-cell carcinomas. These may possibly represent sec-
ondary aberrations that influence the tumor differentiation
pattern.
Conclusions
We have shown that aberrations such as gain of material
from 8q23 and losses from 19q and 22q, previously de-
scribed at high frequencies in bilateral and borderline
ovarian carcinomas, are also present in tumors of more
advanced stages, i.e., carcinomas; this highlights the pos-
sibility of an adenoma-carcinoma sequence in ovarian
carcinogenesis. The low-grade carcinomas may represent
a phenotypically more advanced stage of borderline
tumors.
Additional file
Additional file 1: Table S1. Overview of the genomic aberrations
found in carcinomas of the ovary, detected by karyotyping and HR-CGH.
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